Latest Map Pharmaceuticals (MAPP) Headlines Mat
Post# of 1
Posted On: 03/13/2014 10:50:54 AM
Latest Map Pharmaceuticals (MAPP) Headlines
Mattersight Announces Fourth Quarter 2013 Results
Marketwire - Wed Feb 12, 3:44PM CST
Mattersight Corporation (NASDAQ: MATR) today announced financial results for the fourth quarter ended December 31, 2013.
NV Energy Completes Tender Offers for Outstanding Notes
PR Newswire - Fri Jan 24, 11:11AM CST
NV Energy, Inc. and its wholly owned subsidiaries, Nevada Power Company d/b/a NV Energy and Sierra Pacific Power Company d/b/a NV Energy (collectively, the "Companies"), announced today that each has completed tender offers for certain series of notes as further described below. The tender offers were commenced on December 19, 2013, following the closing of the merger of Silver Merger Sub, Inc., a wholly owned subsidiary of MidAmerican Energy Holdings Company ("MidAmerican"), with and into NV Energy, Inc. (the "Merger") pursuant to the Agreement and Plan of Merger dated May 29, 2013. MidAmerican is an indirect wholly-owned subsidiary of Berkshire Hathaway Inc. The terms and conditions of each offer were set forth in a Change of Control Notice and Offer to Purchase, dated December 19, 2013, issued by NV Energy, Inc., Nevada Power Company, or Sierra Pacific Power Company, respectively.
EarthLink To Announce Fourth Quarter And Full Year 2013 Earnings
PR Newswire - Thu Jan 23, 1:36PM CST
EarthLink Holdings Corp. (NASDAQ: ELNK) today announced it will host a conference call on Thursday, February 20, 2014 at 8:30 a.m. EST to discuss its fourth quarter and full year 2013 financial results. EarthLink plans to issue its earnings press release after market close on Wednesday, February 19.
Huntsman Performance Products to Expand Global Polyetheramines Capacity
PR Newswire - Thu Jan 23, 6:00AM CST
The Performance Products division of Huntsman Corporation (NYSE:HUN) announced today that it will expand its global polyetheramines (PEA) capacity by a minimum of 15 percent as a result of debottlenecking three of its PEA manufacturing plants globally. The financial investment and capacity was not disclosed.
ProductionHUB Modernizes the Hiring Process for Jobseekers in Video Trade Unions
Marketwire - Tue Jan 14, 9:02AM CST
ProductionHUB, the pro video marketplace, makes it easier to hire video production professionals in relevant trade unions.
Analyse Trends and Forecasts in the Drug Delivery Partnering Terms and Agreements Report for 2013
M2 - Thu Jan 09, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvlwqp/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains over 2,600 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking. Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand. Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - 3M Drug Delivery Systems - 3SBio - AMAG Pharmaceuticals - Apricus Biosciences - Aradigm - BioMimetic Therapeutics - Cephalon - Cepheid - Forest Laboratories - GPC Biotech - Galapagos - Indevus Pharmaceuticals - Ipsen - Isis Pharmaceuticals - Kunwha Pharmaceuticals - Lundbeck - Lupin Pharmaceuticals - MAP Pharmaceuticals - Mylan Laboratories - Nektar Therapeutics - Novartis - SignPath Pharmaceuticals - SkyePharma - Solvay - Teva Pharmaceuticals - Uluru - Unigene Laboratories - Xi'an Zaolutang Kushidai Pharmaceuticals - Yakult Honsha - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/wv...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Civitas Therapeutics Appoints Timothy S. Nelson as Chairman of the Board of Directors
Business Wire - Wed Jan 08, 7:14AM CST
Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson's disease that utilizes the proprietary ARCUS(TM) respiratory delivery platform, today announced the appointment of Timothy S. Nelson as Chairman of the Board of Directors. Civitas also announced today that it has completed enrollment in its ongoing Phase 2b clinical study for its lead compound CVT-301, with data expected by the end of the first quarter of this year. CVT-301 is being developed as an adjunct, as needed (PRN) therapy to potentially provide rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes) that affect many Parkinson's disease patients.
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics - 2013: Fully Revised and Updated
M2 - Mon Nov 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdd85f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 9th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2007 to end of Sep 2013. This report contains over 850 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Companies Mentioned: - Abbott Japan - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Celgene - Dyax - Dynavax Technologies - Eisai - Eli Lilly - Enanta Pharmaceuticals - Endo Pharmaceuticals - Exelixis - Facet Biotechnology - Forest Laboratories - Genentech - GlaxoSmithKline - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Macrogenics - MAP Pharmaceuticals - Maxygen - Merck and Co - Novartis - Nycomed - OncoGenex Pharmaceuticals - Pfizer - Procter & Gamble Pharmaceuticals - Purdue Pharma - Regeneron Pharmaceuticals - Salix Pharmaceuticals - Schering-Plough - Solvay - TAP Pharmaceutical - Teva Pharmaceuticals - Tibotec - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/vd...motion_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Allergan shares fall on delay of eye drug study
AP - Wed May 01, 1:51PM CDT
IRVINE, Calif. (AP) — Shares of cosmetic drug and device maker Allergan Inc. fell 12 percent Wednesday after company executives said they would delay late-stage testing of an experimental eye treatment by one to two years.
WEALTHMAKERS.COM Issues Bearish Research Reports on ASIA, BFDI, ECTY, HJN, KTH, MAPP
M2 - Mon Apr 15, 10:52AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Asiainfo Linkage Inc (NASDAQ:ASIA), Brekford Corp (OTCBB:BFDI), ECOtality Inc (NASDAQ:ECTY), Saturns Goldman Sachs Capital I (NYSE:HJN), Structured Products Corp. 8.0% CorporateBacked Trust Securities Certifi (NYSE:KTH), MAP Pharmaceuticals Inc (NASDAQ:MAPP)
Surveyed MCO Pharmacy Directors are Highly Receptive to New Acute Migraine Therapies that Offer Improved Sustained Pain Freedom
PR Newswire - Wed Apr 03, 10:45AM CDT
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that sustained pain freedom beyond two hours is one of the attributes that most influences their decisions when prescribing acute treatments for migraine. Clinical data and the opinions of interviewed thought leaders indicate that, among emerging therapies, orally inhaled dihydroergotamine (MAP Pharmaceuticals/Allergan's Levadex) and sumatriptan intranasal powder (OptiNose) have advantages over sales-leading rizatriptan oral (Merck's Maxalt, Maxalt MLT, generics) on this attribute.
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Allergan Reaches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 05, 5:38PM CST
Shares of Allergan hit a 52-week high of $109.74
Allergan - MAP Acquisition Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 04, 4:30PM CST
Allergan announced that the tender offer to purchase the shares of MAP Pharmaceuticals has expired.
65.4% Return Seen to Date on SmarTrend MAP Pharmaceuticals Call (MAPP)
Comtex SmarTrend(R) - Mon Mar 04, 9:17AM CST
SmarTrend identified an Uptrend for MAP Pharmaceuticals (NASDAQ:MAPP) on November 23rd, 2012 at $15.11. In approximately 3 months, MAP Pharmaceuticals has returned 65.38% as of today's recent price of $24.98.
Allergan, Inc. Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. and Intent to Exercise Top-Up Option to Effect a Short-Form Merger
Business Wire - Fri Mar 01, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan") today announced the expiration of the tender offer (the "Offer") initiated by its wholly-owned subsidiary, Groundhog Acquisition, Inc. ("Purchaser"), on January 31, 2013 to purchase all of the outstanding shares of common stock of MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) ("MAP") for $25.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, as set forth in the Tender Offer Statement on Schedule TO filed by Purchaser and Allergan with the U.S. Securities and Exchange Commission on January 31, 2013. The Offer and withdrawal rights expired at 12:00 midnight, New York City time, on the night of February 28, 2013.
MAPP, MBT, KIRK Expected To Be Down Before Next Earnings Releases
M2 - Fri Mar 01, 5:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and June earnings reports. MAP Pharmaceuticals Inc (NASDAQ:MAPP), Manitoba Telecom Services Inc (NYSE:MBT), Kirklands Inc (NASDAQ:KIRK) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrig
Uptrend Call Working As MAP Pharmaceuticals Stock Rises 65.1% (MAPP)
Comtex SmarTrend(R) - Sat Feb 23, 8:45AM CST
SmarTrend identified an Uptrend for MAP Pharmaceuticals (NASDAQ:MAPP) on November 23rd, 2012 at $15.11. In approximately 3 months, MAP Pharmaceuticals has returned 65.11% as of today's recent price of $24.94.
Pharma Buyout With a 60% Premium
mthiessen@kingsgateinvestments.ca (Mike Thiessen)via The Motley Fool - Motley Fool - Tue Feb 12, 1:20PM CST
Irvine, California-based healthcare company Allergan (NYSE: AGN) has announced its intention to purchase Mountain View, California-based MAP Pharmaceuticals (NASDAQ: MAPP) in a complex tender deal valued at about $960 billion. The...
Mattersight Announces Fourth Quarter 2013 Results
Marketwire - Wed Feb 12, 3:44PM CST
Mattersight Corporation (NASDAQ: MATR) today announced financial results for the fourth quarter ended December 31, 2013.
NV Energy Completes Tender Offers for Outstanding Notes
PR Newswire - Fri Jan 24, 11:11AM CST
NV Energy, Inc. and its wholly owned subsidiaries, Nevada Power Company d/b/a NV Energy and Sierra Pacific Power Company d/b/a NV Energy (collectively, the "Companies"), announced today that each has completed tender offers for certain series of notes as further described below. The tender offers were commenced on December 19, 2013, following the closing of the merger of Silver Merger Sub, Inc., a wholly owned subsidiary of MidAmerican Energy Holdings Company ("MidAmerican"), with and into NV Energy, Inc. (the "Merger") pursuant to the Agreement and Plan of Merger dated May 29, 2013. MidAmerican is an indirect wholly-owned subsidiary of Berkshire Hathaway Inc. The terms and conditions of each offer were set forth in a Change of Control Notice and Offer to Purchase, dated December 19, 2013, issued by NV Energy, Inc., Nevada Power Company, or Sierra Pacific Power Company, respectively.
EarthLink To Announce Fourth Quarter And Full Year 2013 Earnings
PR Newswire - Thu Jan 23, 1:36PM CST
EarthLink Holdings Corp. (NASDAQ: ELNK) today announced it will host a conference call on Thursday, February 20, 2014 at 8:30 a.m. EST to discuss its fourth quarter and full year 2013 financial results. EarthLink plans to issue its earnings press release after market close on Wednesday, February 19.
Huntsman Performance Products to Expand Global Polyetheramines Capacity
PR Newswire - Thu Jan 23, 6:00AM CST
The Performance Products division of Huntsman Corporation (NYSE:HUN) announced today that it will expand its global polyetheramines (PEA) capacity by a minimum of 15 percent as a result of debottlenecking three of its PEA manufacturing plants globally. The financial investment and capacity was not disclosed.
ProductionHUB Modernizes the Hiring Process for Jobseekers in Video Trade Unions
Marketwire - Tue Jan 14, 9:02AM CST
ProductionHUB, the pro video marketplace, makes it easier to hire video production professionals in relevant trade unions.
Analyse Trends and Forecasts in the Drug Delivery Partnering Terms and Agreements Report for 2013
M2 - Thu Jan 09, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvlwqp/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains over 2,600 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking. Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand. Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - 3M Drug Delivery Systems - 3SBio - AMAG Pharmaceuticals - Apricus Biosciences - Aradigm - BioMimetic Therapeutics - Cephalon - Cepheid - Forest Laboratories - GPC Biotech - Galapagos - Indevus Pharmaceuticals - Ipsen - Isis Pharmaceuticals - Kunwha Pharmaceuticals - Lundbeck - Lupin Pharmaceuticals - MAP Pharmaceuticals - Mylan Laboratories - Nektar Therapeutics - Novartis - SignPath Pharmaceuticals - SkyePharma - Solvay - Teva Pharmaceuticals - Uluru - Unigene Laboratories - Xi'an Zaolutang Kushidai Pharmaceuticals - Yakult Honsha - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/wv...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Civitas Therapeutics Appoints Timothy S. Nelson as Chairman of the Board of Directors
Business Wire - Wed Jan 08, 7:14AM CST
Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson's disease that utilizes the proprietary ARCUS(TM) respiratory delivery platform, today announced the appointment of Timothy S. Nelson as Chairman of the Board of Directors. Civitas also announced today that it has completed enrollment in its ongoing Phase 2b clinical study for its lead compound CVT-301, with data expected by the end of the first quarter of this year. CVT-301 is being developed as an adjunct, as needed (PRN) therapy to potentially provide rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes) that affect many Parkinson's disease patients.
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics - 2013: Fully Revised and Updated
M2 - Mon Nov 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdd85f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 9th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2007 to end of Sep 2013. This report contains over 850 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Companies Mentioned: - Abbott Japan - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Celgene - Dyax - Dynavax Technologies - Eisai - Eli Lilly - Enanta Pharmaceuticals - Endo Pharmaceuticals - Exelixis - Facet Biotechnology - Forest Laboratories - Genentech - GlaxoSmithKline - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Macrogenics - MAP Pharmaceuticals - Maxygen - Merck and Co - Novartis - Nycomed - OncoGenex Pharmaceuticals - Pfizer - Procter & Gamble Pharmaceuticals - Purdue Pharma - Regeneron Pharmaceuticals - Salix Pharmaceuticals - Schering-Plough - Solvay - TAP Pharmaceutical - Teva Pharmaceuticals - Tibotec - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/vd...motion_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Allergan shares fall on delay of eye drug study
AP - Wed May 01, 1:51PM CDT
IRVINE, Calif. (AP) — Shares of cosmetic drug and device maker Allergan Inc. fell 12 percent Wednesday after company executives said they would delay late-stage testing of an experimental eye treatment by one to two years.
WEALTHMAKERS.COM Issues Bearish Research Reports on ASIA, BFDI, ECTY, HJN, KTH, MAPP
M2 - Mon Apr 15, 10:52AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Asiainfo Linkage Inc (NASDAQ:ASIA), Brekford Corp (OTCBB:BFDI), ECOtality Inc (NASDAQ:ECTY), Saturns Goldman Sachs Capital I (NYSE:HJN), Structured Products Corp. 8.0% CorporateBacked Trust Securities Certifi (NYSE:KTH), MAP Pharmaceuticals Inc (NASDAQ:MAPP)
Surveyed MCO Pharmacy Directors are Highly Receptive to New Acute Migraine Therapies that Offer Improved Sustained Pain Freedom
PR Newswire - Wed Apr 03, 10:45AM CDT
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that sustained pain freedom beyond two hours is one of the attributes that most influences their decisions when prescribing acute treatments for migraine. Clinical data and the opinions of interviewed thought leaders indicate that, among emerging therapies, orally inhaled dihydroergotamine (MAP Pharmaceuticals/Allergan's Levadex) and sumatriptan intranasal powder (OptiNose) have advantages over sales-leading rizatriptan oral (Merck's Maxalt, Maxalt MLT, generics) on this attribute.
Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi
Allergan Reaches 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 05, 5:38PM CST
Shares of Allergan hit a 52-week high of $109.74
Allergan - MAP Acquisition Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 04, 4:30PM CST
Allergan announced that the tender offer to purchase the shares of MAP Pharmaceuticals has expired.
65.4% Return Seen to Date on SmarTrend MAP Pharmaceuticals Call (MAPP)
Comtex SmarTrend(R) - Mon Mar 04, 9:17AM CST
SmarTrend identified an Uptrend for MAP Pharmaceuticals (NASDAQ:MAPP) on November 23rd, 2012 at $15.11. In approximately 3 months, MAP Pharmaceuticals has returned 65.38% as of today's recent price of $24.98.
Allergan, Inc. Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. and Intent to Exercise Top-Up Option to Effect a Short-Form Merger
Business Wire - Fri Mar 01, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan") today announced the expiration of the tender offer (the "Offer") initiated by its wholly-owned subsidiary, Groundhog Acquisition, Inc. ("Purchaser"), on January 31, 2013 to purchase all of the outstanding shares of common stock of MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) ("MAP") for $25.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, as set forth in the Tender Offer Statement on Schedule TO filed by Purchaser and Allergan with the U.S. Securities and Exchange Commission on January 31, 2013. The Offer and withdrawal rights expired at 12:00 midnight, New York City time, on the night of February 28, 2013.
MAPP, MBT, KIRK Expected To Be Down Before Next Earnings Releases
M2 - Fri Mar 01, 5:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and June earnings reports. MAP Pharmaceuticals Inc (NASDAQ:MAPP), Manitoba Telecom Services Inc (NYSE:MBT), Kirklands Inc (NASDAQ:KIRK) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrig
Uptrend Call Working As MAP Pharmaceuticals Stock Rises 65.1% (MAPP)
Comtex SmarTrend(R) - Sat Feb 23, 8:45AM CST
SmarTrend identified an Uptrend for MAP Pharmaceuticals (NASDAQ:MAPP) on November 23rd, 2012 at $15.11. In approximately 3 months, MAP Pharmaceuticals has returned 65.11% as of today's recent price of $24.94.
Pharma Buyout With a 60% Premium
mthiessen@kingsgateinvestments.ca (Mike Thiessen)via The Motley Fool - Motley Fool - Tue Feb 12, 1:20PM CST
Irvine, California-based healthcare company Allergan (NYSE: AGN) has announced its intention to purchase Mountain View, California-based MAP Pharmaceuticals (NASDAQ: MAPP) in a complex tender deal valued at about $960 billion. The...
(0)
(0)Map Pharmaceuticals (MAPP) Stock Research Links
Scroll down for more posts ▼